ArticleBMJ paediatrics open2025
Prevalence of drug-drug interactions in children with cardiac disorders receiving off-label drugs in a single centre in Pakistan: a cross-sectional study.
Article in BMJ paediatrics open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study evaluated the prevalence of clinically significant drug-drug interactions (CSDDIs), off-label (OL) drug use and the associated predictors in paediatric cardiology ward.
designA cross-sectional study.
settingHayatabad Medical Complex, Tertiary care hospital in Peshawar, Pakistan. PATIENTS: 250 patients. METHODOLOGY: The Micromedex Drug-Reax tool was used to check the drug-drug interactions (DDI) and interactions of major severity were categorised as CSDDI. Association of various predictors including OL drug use with CSDDIs was evaluated using univariate and multivariate binary logistic regression.
main outcome measuresRate of drug-drug interactions, types and classification of DDI, OL prescribing in paediatrics.
resultOf the total 250 paediatric patients, 127 (28.6%) patients were exposed to at least one clinically significant DDI, while 228 (91.20%) patients received at least one OL prescription. Furosemide was the most frequently prescribed drug involved in CSDDIs, while it was also one of the highly prescribed OL drugs. Multivariate analysis revealed that infant age group (OR 0.256; CI 0.080 to 0.814) with p value 0.02 and patients prescribed >5 drugs (OR 3.544; CI 1.906 to 6.589) were significantly more likely to experience CSDDIs in reference to their corresponding categories.
conclusionA high prevalence of CSDDIs and OL prescriptions was observed. OL drug presence was also observed to be a significant predictor associated with an increased risk of CSDDIs. Thus, to improve paediatric pharmacotherapy, suitable medical interventions are required to decrease OL drug use and CSDDIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.